Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Summary

This is a two center, open label, non-randomized Phase II study of lenvatinib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR signaling. Treatment will consist of daily oral administration of Lenvatinib in 28-day cycles.

Timeline

Start

2018-07-01

Primary completion

2020-06-01

Completion

2021-06-01

Outcome

Outcome not reported

Stopped: “Unable to execute a contract agreement with the drug manufacturer.”

Drugs

Indications